Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Industry News

New study finds both components of blood pressure predict heart attack, stroke risk

July 17, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Industry News

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

April 16, 2019

News Industry News

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic

September 19, 2017

News Industry News

Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology for Heart Failure Patients

July 20, 2017

News Industry News

Medtronic First to Receive FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers

May 11, 2017

News Industry News

LivaNova Launches Next Generation ICD and CRT-D Devices in the United States

September 23, 2016

News Industry News

Medtronic Receives FDA Approval for New Single-Chamber ICDs That Detect Atrial Fibrillation

May 02, 2016

News Industry News

Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators

February 04, 2016

News Industry News

New Long-term Data Published in The Lancet Further Demonstrates Superiority of the CardioMEMS HF System over Standard of Care

November 08, 2015

News Industry News

LivaNova Announces the Launch of the PLATINIUM ICD & CRT-D Family Providing the World’s Longest Projected Longevity

November 01, 2015

News Industry News

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

October 21, 2015

News Industry News

Biotronik launches 2 new studies

August 13, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

May 26, 2015

Advertisement

New study finds both components of blood pressure predict heart attack, stroke risk

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic

Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology for Heart Failure Patients

Medtronic First to Receive FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers

LivaNova Launches Next Generation ICD and CRT-D Devices in the United States

Medtronic Receives FDA Approval for New Single-Chamber ICDs That Detect Atrial Fibrillation

Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators

New Long-term Data Published in The Lancet Further Demonstrates Superiority of the CardioMEMS HF System over Standard of Care

LivaNova Announces the Launch of the PLATINIUM ICD & CRT-D Family Providing the World’s Longest Projected Longevity

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

Biotronik launches 2 new studies

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content